TY - JOUR
T1 - Prevalence of Post-Chikungunya Infection Chronic Inflammatory Arthritis
T2 - A Systematic Review and Meta-Analysis
AU - Rodríguez-Morales, Alfonso J.
AU - Cardona-Ospina, Jaime A.
AU - Fernanda Urbano-Garzón, Sivia
AU - Sebastian Hurtado-Zapata, Juan
N1 - Publisher Copyright:
© 2016, American College of Rheumatology
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Objective: To determine the percentage of patients who would develop chronic inflammatory rheumatism (CIR) following chikungunya (CHIK) virus disease. Methods: We conducted a systematic review of the literature in 3 databases (PubMed, Science Citation Index, and Scopus) to identify studies assessing the proportion of patients who progress to CHIK-CIR. We performed a random-effects model meta-analysis to calculate the pooled prevalence and 95% confidence intervals (95% CIs). A 2-tailed alpha level of 5% was used for hypothesis testing. Measures of heterogeneity, including Cochran's Q statistic, the I2 index, and the tau-squared test, were calculated and reported. Subgroup analyses were conducted by type of study and country, by studies evaluating chronic arthritis, and by studies with ≥200 patients and followup ≥18 months. Publication bias was assessed using a funnel-plot. Results: Up to June 15, 2015, our literature search yielded 578 citations. The pooled prevalence of CHIK-CIR in 18 selected studies among 5,702 patients was 40.22% (95% CI 31.11–49.34; τ2 = 0.0838). From studies derived from India, prevalence was 27.27% (95% CI 15.66–38.88; τ2 = 0.0411), while from France, prevalence was 50.25% (95% CI 25.38–75.12; τ2 = 0.1797). The prevalence of CHIK chronic arthritis was 13.66% (95% CI 9.31–18.00; τ2 = 0.0060). Considering just those studies with ≥200 patients assessed, prevalence was 34.14% (95% CI 23.99–44.29; τ2 = 0.0525). In studies with a followup ≥18 months, prevalence was 32.13% (95% CI 22.21–42.04; τ2 = 0.0453). Conclusion: According to our results in the most conservative scenario, approximately 25% of CHIK cases would develop CHIK-CIR (34% if we just consider the most representative studies), and 14% would develop chronic arthritis.
AB - Objective: To determine the percentage of patients who would develop chronic inflammatory rheumatism (CIR) following chikungunya (CHIK) virus disease. Methods: We conducted a systematic review of the literature in 3 databases (PubMed, Science Citation Index, and Scopus) to identify studies assessing the proportion of patients who progress to CHIK-CIR. We performed a random-effects model meta-analysis to calculate the pooled prevalence and 95% confidence intervals (95% CIs). A 2-tailed alpha level of 5% was used for hypothesis testing. Measures of heterogeneity, including Cochran's Q statistic, the I2 index, and the tau-squared test, were calculated and reported. Subgroup analyses were conducted by type of study and country, by studies evaluating chronic arthritis, and by studies with ≥200 patients and followup ≥18 months. Publication bias was assessed using a funnel-plot. Results: Up to June 15, 2015, our literature search yielded 578 citations. The pooled prevalence of CHIK-CIR in 18 selected studies among 5,702 patients was 40.22% (95% CI 31.11–49.34; τ2 = 0.0838). From studies derived from India, prevalence was 27.27% (95% CI 15.66–38.88; τ2 = 0.0411), while from France, prevalence was 50.25% (95% CI 25.38–75.12; τ2 = 0.1797). The prevalence of CHIK chronic arthritis was 13.66% (95% CI 9.31–18.00; τ2 = 0.0060). Considering just those studies with ≥200 patients assessed, prevalence was 34.14% (95% CI 23.99–44.29; τ2 = 0.0525). In studies with a followup ≥18 months, prevalence was 32.13% (95% CI 22.21–42.04; τ2 = 0.0453). Conclusion: According to our results in the most conservative scenario, approximately 25% of CHIK cases would develop CHIK-CIR (34% if we just consider the most representative studies), and 14% would develop chronic arthritis.
UR - http://www.scopus.com/inward/record.url?scp=84992313445&partnerID=8YFLogxK
U2 - 10.1002/acr.22900
DO - 10.1002/acr.22900
M3 - Artículo
C2 - 27015439
AN - SCOPUS:84992313445
SN - 2151-464X
VL - 68
SP - 1849
EP - 1858
JO - Arthritis Care and Research
JF - Arthritis Care and Research
IS - 12
ER -